O’Neil Health Care Weekly

XLV pulled back 2.7% after finding resistance directly at its rolling 50-DMA ($131.84). Despite the pullback, its RS line
continues to hold, remaining near recent highs. Look for the index to remain in a range and hold support above $124.

Market View

The U.S. market remains in a Rally Attempt. The S&P 500 and Nasdaq were unable to rally above 10-DMA resistance (S&P 500: 4,275; Nasdaq: 13,207), reversing from that level again Friday. Despite poor technical action, both indices remain above the February 24 low, keeping the attempted rally alive. Monday will mark Day 13 of the Rally Attempt with a follow-through day still needed to upgrade the market status. An undercut of these lows will shift the market status back to Downtrend.

O’Neil Health Care Weekly

XLV rallied for a second straight week and now faces resistance at its declining 50-DMA ($132.91). Its RS line continues to rise as bigger cap constituents across Managed Care and Pharma remain under accumulation.  We will be looking for the index to regain and hold above the 50-DMA this week. Should it reverse, look for support at the rising 10- 21- or 200-DMA, all of which are just below current prices.

Market View

The U.S. market remains in a Rally Attempt. The S&P 500 and Nasdaq bounced into resistance at their declining 21-
DMA (S&P 500: 4,394; Nasdaq: 13,756) before pulling back for the week. Price action continues to be volatile however the
Rally Attempt status remains once indices hold above February 24th lows (S&P 500: 4,288; Nasdaq: 13,473). While in a
Rally Attempt, the market status moves to a Confirmed Uptrend

O’Neil Health Care Weekly

Pacira Biosciences (PCRX) — $2.9B market cap — Buy Pacira Biosciences as the stock is breaking out of a 52-week
stage-one cup-with-handle base in heavy volume. Exparel (88% of revenue) is the only approved non-opioid long acting
pre and post surgery pain medication with a TAM of 32M patients annually. The company is poised for strong double-digit
growth over the next few years driven by a rebound in elective surgeries, geographic expansion, and portfolio
diversification.

Market View

The U.S. market is in a Downtrend. The S&P 500 and Nasdaq undercut January lows before reversing sharply higher
to close a volatile shortened week. Both are now two days off recent lows and still below near-term resistance at their
respective 21-DMA (S&P 500: 4,423; Nasdaq: 13,881) before both the 50 – and 200-DMA. The market status will shift to
Rally Attempt Monday should recent lows hold at which point a second follow-through day will need to occur before
moving back to Confirmed Uptrend

O’Neil Health Care Weekly

XLV fell another 2% last week, moving further below its 200-DMA and now set to test support at ~$124.50. This level held
in October and again in January. Near-term moving averages are rolling over and may act as resistance before the 200-
DMA ($130.80). The 21-DMA is currently trading at $131.10.

Market View

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq reversed from 21-DMA resistance,
closing near the lows of the week and adding additional distribution. There is no clear level of support until January lows
(S&P 500: 4,222; Nasdaq: 13,094). The distribution day count increased to four and five, respectively

Market View

The U.S. market remains in a Confirmed Uptrend. The market status will shift to Uptrend Under Pressure should either index close below the follow-through day lows (S&P 500: 4,414; Nasdaq: 13,767). Thus far, there are multiple indications that this rally may fail, given there has been no progress above key moving-average resistance and multiple distribution days occurring within just two weeks of the follow-though. Distribution now stands at two and three, respectively.